NAGAILEBEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,351 JPY | +0.86% |
|
+3.30% | -1.30% |
| Apr. 02 | Nagaileben Co., Ltd. announces an Equity Buyback for 500,000 shares, representing 1.57% for ¥1,000 million. | CI |
| Apr. 02 | Nagaileben Co., Ltd. authorizes a Buyback Plan. | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The group's high margin levels account for strong profits.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company benefits from high valuations in earnings multiples.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Most analysts recommend that the stock should be sold or reduced.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -1.30% | 475M | - | ||
| +11.84% | 27.79B | B+ | ||
| -32.98% | 2.98B | B- | ||
| -15.97% | 2.52B | C+ | ||
| +11.90% | 2.34B | - | A- | |
| -1.11% | 1.91B | B | ||
| -13.37% | 1.83B | - | ||
| -7.78% | 1.39B | B | ||
| -0.38% | 1.27B | - | ||
| +4.01% | 1.13B | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
-
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 7447 Stock
- Ratings Nagaileben Co., Ltd.
